Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MLYCD | O95822 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29537198 | 0.98 | SIGMAR1 (0.42) | SIGMAR1MLYCDTSHRTDP1NAMPT | |
| SCHEMBL13046403 | 0.86 | MAOA (0.36) | SIGMAR1MLYCDTSHRTDP1 | |
| SCHEMBL14003762 | 0.84 | KDM4E (0.39) | TDP1 | |
| SCHEMBL3392437 | 0.83 | GRM4 (0.38) | SIGMAR1MLYCDTSHRTDP1MTNR1A | |
| SCHEMBL15270731 | 0.81 | MLYCD (0.36) | SIGMAR1MLYCDTSHRTDP1MTNR1A | |
| SCHEMBL14592848 | 0.81 | SIGMAR1 (0.41) | SIGMAR1MLYCDNAMPTCSNK1ECCKBR | |
| SCHEMBL13589877 | 0.79 | SIGMAR1 (0.46) | SIGMAR1MLYCDNAMPTCCKBRHSD17B13 | |
| SCHEMBL19543467 | 0.79 | SIGMAR1 (0.46) | SIGMAR1MLYCD | |
| SCHEMBL15270026 | 0.78 | MLYCD (0.34) | MLYCDTSHRTDP1 | |
| SCHEMBL13068775 | 0.78 | TDP1 (0.39) | TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585242-A | RAF kinase inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11702448-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032071-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-20180194803-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | RHYTHM PHARMACEUTICALS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-20080009504-A1 | Antifungal agents | SCYNEXIS, INC. | 2008-01-10 | — | — | US | disclosed |
| EP-1085009-B1 | INDAN DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-0934296-B1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6486178-B1 | Indane derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-26 | — | — | US | disclosed |
| EP-1085009-A1 | INDAN DERIVATIVES | Nissan Chemical Industries, Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| US-6066631-A | Chroman derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| WO-2000012492-A1 | BENZOXAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
| CN-1226243-A | Benzodihydropyran derivative | NISSAN CHEMICAL IND LTD (JP) | 1999-08-18 | — | — | CN | disclosed |
| EP-0934296-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004542-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | SIGMAR1 3912/4885MLYCD 2021/4885TSHR 2473/4885 |
| US-20080009504-A1 | Antifungal agents | DPM1, MAN2B1, MAN2A1 | SIGMAR1 4032/4885MLYCD 434/4885TSHR 4788/4885 |
| US-11702448-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | MC4R, MC1R, MC2R | SIGMAR1 1713/4885MLYCD 1189/4885TSHR 151/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | SIGMAR1 3912/4885MLYCD 2021/4885TSHR 2473/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | SIGMAR1 3774/4885MLYCD 1918/4885TSHR 2408/4885 |
| US-20180194803-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | MC4R, MC1R, MC2R | SIGMAR1 1713/4885MLYCD 1189/4885TSHR 151/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | SIGMAR1 3912/4885MLYCD 2021/4885TSHR 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.